References:
  1. Hashemi, Fallah, Lori Hoepner, FARAHNAZ Soleimani Hamidinejad, Daniela Haluza, Sima Afrashteh, Alireza Abbasi, Elma Omeragić et al. ”A Comprehensive Health Effects Assessment of the Use of Sanitizers and Disinfectants during COVID-19 Pandemic: A Global Survey (preprint).” (2022).
  2. Harfouch, R. M. ”Antiviral Effects of Propolis against SARS-COV 2.”Int J Clin Med Imaging 9 809 (2022).
  3. Harfouch, R. M., S. Alshaikh, M. Alshimaly, A. Assaad, J. Ahmad, H. Zoughaibi, M. Hammadi, and Y. Elshimali. ”Therapeutic approaches for covid 19: Challenges and successes.” Annals of Clinical and Analytical Medicine (2021): 228-233.
  4. Alhouri, Ali, et al. ”Possible side effects of using detergents during the Covid19 pandemic in Syria.” Ann. Clin. Cases 1.4 (2020): 1023.
  5. Harfouch, Rim M. ”Cytokine Storm syndrome in COVID-19 patients: Characteristics And diagnosis.” Journal of Clinical Epidemiology & Toxicology 2.4 (2021): 1-3.
  6. Harfouch, R. M., et al. ”Epidemiology of COVID-19 in the most pandemic Countries: A review article. Acad.” J. Biotechnol 9.1 (2021): 021-027.
  7. Harfouch, Rim. ”Multiple organs failure in COVID-19 patients.”Authorea Preprints (2022).
  8. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dube M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1)
  9. Harfouch, Rim. ”Effect of SARS-COV2 virus on nervous system and mental health.” Authorea Preprints (2022).
  10. Matschke J, Lutgehetmann M, Hagel C, Sperhake JP, Schroder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919–29.
  11. Jarius S, Pache F, Kortvelyessy P, Jelcic I, Stettner M, Franciotta D, et al. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. J Neuroinflammation. 2022;19(1):19.
  12. Coolen T, Lolli V, Sadeghi N, Rovai A, Trotta N, Taccone FS, et al. Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology. 2020;95(14):e2016–27.
  13. Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;144:2696-2708.
  14. Lou JJ, Movassaghi, M & Gordy, D, et al. Neuropathology of COVID-19 (neuro-COVID): clinicopathological update. Free Neuropathol. 2021;Jan 18;2:2.
  15. Jiang T, Zhang Y-D, Zhou J-S, et al. Angiotensin-(1-7) is reduced and inversely correlates with tau hyperphosphorylation in animal models of Alzheimer’s disease. Mol Neurobiol. 2016;53:2489-2497.
  16. Kehoe PG, Wong S, Al Mulhim N, Palmer LE, Miners JS. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology. Alzheimers Res Ther. 2016;8:50.
  17. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–72.
  18. Abate G, Memo M, Uberti D. Impact of COVID-19 on Alzheimer’s disease risk: viewpoint for research action. Healthcare. 2020. https://doi.org/10.3390
  19. Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med. 2015;3(10):136.
  20. Chen, F., Chen, Y., Wang, Y. et al. The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms. Transl Neurodegener 11 , 40 (2022). https://doi.org/10.1186/s40035-022-00316-y